XML 14 R5.htm IDEA: XBRL DOCUMENT v3.22.0.1
Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) - USD ($)
Preferred Stock
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Total Citius Pharmaceuticals, Inc. Shareholder’s Equity
Non-Controlling Interest
Total
Balance at Sep. 30, 2020 $ 55,577 $ 104,208,958 $ (70,593,867) $ 33,670,668 $ 33,670,668
Balance (in Shares) at Sep. 30, 2020   55,576,996          
Issuance of NoveCite common stock   1,799,640 (2,399,520) (599,880) 600,380 500
Stock-based compensation expense 276,582 276,582 276,582
Net loss (8,146,909) (8,146,909) (8,146,909)
Balance at Dec. 31, 2020   $ 55,577 106,285,180 (81,140,296) 25,200,461 600,380 25,800,841
Balance (in Shares) at Dec. 31, 2020   55,576,996          
Balance at Sep. 30, 2021 $ 145,979 228,084,195 (96,047,821) 132,182,353 600,380 132,782,733
Balance (in Shares) at Sep. 30, 2021   145,979,429          
Issuance of common stock for services $ 50 95,834 95,884 95,884
Issuance of common stock for services (in Shares)   50,201          
Stock-based compensation expense 904,604 904,604 904,604
Net loss (9,225,220) (9,225,220) (9,225,220)
Balance at Dec. 31, 2021   $ 146,029 $ 229,084,633 $ (105,273,041) $ 123,957,621 $ 600,380 $ 124,558,001
Balance (in Shares) at Dec. 31, 2021   146,029,630